Mucosal melanoma(MM)is a rare melanoma that affects the mucous membranes of the gastrointestinal,respiratory,and genitourinary tracts[1].In contrast to cutaneous melanoma(CM),MM occurs in body areas without sun exposu...Mucosal melanoma(MM)is a rare melanoma that affects the mucous membranes of the gastrointestinal,respiratory,and genitourinary tracts[1].In contrast to cutaneous melanoma(CM),MM occurs in body areas without sun exposure and is more difficult to detect,often overlooked until nodal or metastatic involvement[2].The molecular profile of MM is distinct,with a lower mutational burden and higher degree of chromosomal aberrations than CM,potentially affecting treatment strategies[3].Patients with MM typically receive the same immunotherapy as patients with CM and are not candidates for BRAF/MEK inhibition,an option for many patients with CM[1].However,standard-of-care therapies and immune checkpoint inhibitors(ICIs)are associated with poor outcomes in patients with MM[4–6].展开更多
基金This study was sponsored by Iovance Biotherapeutics,Inc.(San Carlos,CA,USA).
文摘Mucosal melanoma(MM)is a rare melanoma that affects the mucous membranes of the gastrointestinal,respiratory,and genitourinary tracts[1].In contrast to cutaneous melanoma(CM),MM occurs in body areas without sun exposure and is more difficult to detect,often overlooked until nodal or metastatic involvement[2].The molecular profile of MM is distinct,with a lower mutational burden and higher degree of chromosomal aberrations than CM,potentially affecting treatment strategies[3].Patients with MM typically receive the same immunotherapy as patients with CM and are not candidates for BRAF/MEK inhibition,an option for many patients with CM[1].However,standard-of-care therapies and immune checkpoint inhibitors(ICIs)are associated with poor outcomes in patients with MM[4–6].
